Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year

Real-world data on guselkumab, especially at times >6 months, are limited. We performed a longitudinal, retrospective analysis on 307 patients with moderate–severe chronic plaque psoriasis (Psoriasis Area Severity Index [PASI] >10) treated with guselkumab for up to 12 months. PASI 75, PASI 90, and PASI 100 were assessed at baseline and at 4, 12, 20, 28, 36, 44, and 52 weeks. At 12 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 56.4%, 33.6%, and 24.1% of patients, respectively. At 52 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 82.7%, 68.7%, and 51.1% of patients, respectively. Patients without comorbidities and those naïve to previous biological therapy had better responses. The mean Dermatology Life Quality Index score decreased from 14.0 at baseline to 3.1 at 12 weeks and 1.6 at 6 months, which was maintained at later times. Similar improvements were seen in pruritus visual analog scale. Guselkumab maintains its efficacy for up to 12 months among responders in a real-world cohort of patients with moderate–severe plaque psoriasis, confirming data from prior real-world studies with smaller cohorts and shorter duration of follow-up.

目前关于古塞库单抗（guselkumab）的真实世界数据较为有限，尤其是用药时长超过6个月的相关数据更为匮乏。我们对307例中度至重度慢性斑块状银屑病患者（银屑病面积和严重程度指数（Psoriasis Area Severity Index，PASI）＞10）开展了一项纵向回顾性分析，所有患者均接受古塞库单抗治疗，最长随访时长达12个月。研究分别在基线及第4、12、20、28、36、44、52周时，评估患者的PASI 75、PASI 90及PASI 100达标情况。治疗12周时，分别有56.4%、33.6%及24.1%的患者实现PASI 75、PASI 90及PASI 100达标；至52周时，该比例分别升至82.7%、68.7%及51.1%。无合并症患者及既往未接受过生物制剂治疗的患者应答效果更佳。患者的皮肤病生活质量指数（Dermatology Life Quality Index）平均得分从基线时的14.0降至12周时的3.1，6个月时进一步降至1.6，且后续随访时段该得分维持稳定。瘙痒视觉模拟评分也呈现出相似的改善趋势。在本次中度至重度斑块状银屑病真实世界队列的应答患者中，古塞库单抗的疗效可维持长达12个月，这一结果验证了此前小样本队列、随访时长更短的真实世界研究数据。